 - Pelareorep and atezolizumab synergize the anti-cancer immune response in HRHER2- breast cancer patients - Pelareorep alone and with checkpoint blockade converts tumors to PD-L1 positive classification - Oncolytics validates that pelareorep significantly improves immunotherapies - Company management hosting a KOL event today at 2:00 pm ET SAN DIEGO and CALGARY, Alberta, April 12, 2021 PRNewswire -- Oncolytics Biotech Inc. NASDAQ: ONCY TSX: ONC, together with SOLTI, recently announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study showing patients receiving pelareorep plus checkpoint blockade therapy met the trials primary endpoint. These data are featured in an electronic poster at the American Association for Cancer Research AACR Annual Meeting 2021 during Week 1, which is taking place virtually from April 10-15, 2021. 